Stepwise Pharmacologic Management of Asthma
All patients with asthma should have a short-acting β2-agonist (SABA) such as albuterol as rescue therapy, with inhaled corticosteroids (ICS) serving as the cornerstone of maintenance therapy for any level of persistent asthma, escalating to ICS/LABA combinations for moderate-to-severe disease. 1
Rescue Therapy (All Patients)
Short-acting β2-agonists (albuterol, levalbuterol, pirbuterol) are the treatment of choice for acute symptom relief and should be available to all asthma patients 1. These medications work by relaxing airway smooth muscle and provide rapid bronchodilation.
Critical caveat: If you're using your SABA more than 2 days per week for symptom relief (excluding pre-exercise use), this signals inadequate asthma control and necessitates stepping up anti-inflammatory therapy 1. Regular daily scheduled use of SABA is not recommended as it masks underlying inflammation.
Stepwise Controller Therapy
Step 1: Intermittent Asthma
- SABA as needed only 2
Step 2: Mild Persistent Asthma
Preferred: Low-dose inhaled corticosteroids 2, 3
Alternative options (not preferred):
- Leukotriene receptor antagonists (montelukast, zafirlukast)
- Cromolyn or nedocromil
- Theophylline 1
The evidence strongly supports ICS as first-line therapy even for mild persistent asthma, with alternatives relegated to secondary status 3.
Step 3: Moderate Persistent Asthma
Preferred: Low-to-medium dose ICS + long-acting β2-agonist (LABA) 2, 3
Alternative: Medium-dose ICS alone, or low-to-medium dose ICS + leukotriene modifier or theophylline 2
The addition of LABA to ICS is superior to increasing ICS dose alone or adding other medications 3. For youths ≥12 years and adults, LABA is the preferred adjunctive therapy to combine with ICS 1.
Critical safety warning: LABAs must never be used as monotherapy for asthma—they must always be combined with ICS 1.
Step 4: Severe Persistent Asthma
High-dose ICS + LABA 2
Additional adjunctive options:
- Long-acting muscarinic antagonists (tiotropium) 4
- Leukotriene modifiers
- Theophylline (requires serum level monitoring) 1
Step 5-6: Severe Persistent Asthma Requiring Maximum Therapy
High-dose ICS + LABA + oral systemic corticosteroids if needed 2
Biologic therapies for severe allergic/eosinophilic asthma:
- Omalizumab (anti-IgE): For patients ≥12 years with allergen sensitivity (dust mite, cockroach, cat, dog) requiring step 5-6 care 1. Clinicians must be prepared to treat potential anaphylaxis.
- Other biologics (mepolizumab, reslizumab) for eosinophilic phenotypes 4
Acute Exacerbations
For moderate-to-severe exacerbations in emergency settings:
- SABA + ipratropium bromide provides additive benefit 1
- Oral systemic corticosteroids speed recovery and prevent relapse 1
- Intravenous magnesium sulphate may be considered 5
Note that ipratropium provides benefit in the emergency department setting but not in hospital settings 1.
Modern Approach: MART Therapy
Maintenance and Reliever Therapy (MART) using ICS-formoterol as both controller and rescue medication is increasingly preferred for adults and adolescents with moderate-to-severe asthma due to superior reduction in severe exacerbations 6, 7. This represents an evolution from the traditional separate maintenance and rescue inhaler approach, though conventional ICS/LABA + SABA remains appropriate for many patients based on individual characteristics and preferences 8.
Key Clinical Pitfalls to Avoid
- Never prescribe LABA without ICS—this is associated with increased mortality risk
- Don't ignore SABA overuse—using rescue inhaler >2 days/week signals need for controller escalation
- Don't use regular daily SABA—this masks poor control and worsens outcomes
- Monitor theophylline levels if prescribed—narrow therapeutic window
- Monitor liver function with zileuton 1
- Be prepared for anaphylaxis when administering omalizumab